Paul has X-Linked Retinitis Pigmentosa, a rare eye disease with no cure — however, several clinical trials are using gene therapy as a potential way to stop or slow down the sight loss. Paul has enrolled in 3 of these clinical trials, only to be rejected for being “too blind” to participate. If one of these trials becomes FDA approved, Paul (and thousands of others) can take advantage of the treatment, which could happen in the next 5 - 10 years. Whether he goes completely blind or maintains som
0:44
Paul has X-Linked Retinitis Pigmentosa, a rare eye disease with no cure — however, several clinical trials are using gene therapy as a potential way to stop or slow down the sight loss. Paul has enrolled in 3 of these clinical trials, only to be rejected for being “too blind” to participate. If one of these trials becomes FDA approved, Paul (and thousands of others) can take advantage of the treatment, which could happen in the next 5 - 10 years. Whether he goes completely blind or maintains som
170.3K viewsApr 5, 2023
FacebookMatthew and Paul
See more
Static thumbnail place holder